Integrated BioPharma reported a 22% revenue decline to $9.9 million for the quarter ended September 30, 2026, resulting in a net loss of $0.7 million. The company noted significant customer concentration, with its two largest contract manufacturing clients accounting for 88% of total revenue.
Term
Q1 2027
“Our revenue decreased by approximately 22% in the quarter ended September 30, 2026 from the quarter ended September 30, 2025 and our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 88% and 87% of total revenue in the quarters ended September 30, 2026 and 2025, respectively.”
Riva Sheppard and Christina Kay, Co-Chief Executive Officers
Integrated BioPharma reported a net loss of $691,000 for the quarter ended September 30, 2026, compared to a net income of $123,000 in the prior year period, driven by a significant decline in net sales from $12.7 million to $9.9 million. The company experienced a gross loss of $112,000 as cost of sales exceeded revenue, leading to a basic and diluted net loss of $0.02 per share.
Integrated BioPharma reported financial results for its fiscal year ended June 30, 2026, showing a 19.3% revenue decrease to $43.9 million. The company swung to a net loss of $2.8 million ($0.09 per share) compared to a net income of $0.8 million in the prior fiscal year, driven by lower sales and an operating loss of $2.7 million.
Term
FY2026
“Our revenue decreased by approximately 19% in our fiscal year ended June 30, 2026 from the fiscal year ended June 30, 2025 and our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 90% and 84% of total revenue in our fiscal years ended June 30, 2026 and 2025, respectively.”
Riva Sheppard and Christina Kay, Co-Chief Executive Officers